Revision Breast Surgery

GalaFLEX Safety: Palpability, Seroma, Infection, Resorption — and What Regulators Say

2026-11-13

Start with the published numbers

The most informative dataset is a single-surgeon review of 248 patients who received P4HB scaffolds in aesthetic breast surgery between 2012 and 2022 and were followed for a mean of 2.9 years (Sinclair and Adams, Aesthetic Surgery Journal, 2024). The overall complication rate was 8.0 percent and 2.8 percent of patients needed an unplanned second operation; satisfaction stayed stable over time. Those are reassuring figures from a very experienced practice — and they are retrospective, from one centre, in selected patients. A randomized, controlled trial in breast revision has enrolled over 270 patients and is still running; until it reports, this is the quality of evidence a patient is consenting on.

The complications, one by one

Seroma. Any sheet placed in a pocket raises the chance of fluid collecting around it; drains, compression and limiting arm movement are the counters, and a persistent seroma is drained in the clinic. Infection. Uncommon, but consequential: the label states that an unresolved infection may require removing the scaffold, which is why antibiotic irrigation, no-touch technique and early reporting of redness or fever are not optional. Palpability. In thin tissue a firm edge or ridge along the fold is common for the first months; most soften as the polymer is absorbed, a minority remain palpable. Pain and inflammation. A transient inflammatory response is part of how the scaffold is replaced by collagen; prolonged pain is investigated. Exposure and delayed healing. Rare, more likely under tension or in smokers, and treated by local wound care or removal of the exposed portion. Hypersensitivity. Tetracycline and kanamycin are used in manufacturing; patients allergic to either are told that safety has not been studied in their case.

What happens as it resorbs

P4HB loses strength gradually — about half remains at twelve weeks in preclinical testing — while collagen grows through the knit. By 18–24 months resorption is essentially complete and what remains is a layer of the patient's own connective tissue along the line where the scaffold lay. There is no fragment to migrate and no permanent foreign body. The practical consequence: the scaffold's job is to carry the repair through its weakest months and hand over to healed tissue; it is not a lifelong strut, which is why implant weight and aftercare still decide the long-term result.

Who should not have it

Anyone with an active or recent infection in the pocket; a patient whose capsular contracture is being treated on the hope that a scaffold alone will prevent recurrence; patients who cannot or will not follow the garment and movement rules; smokers who will not stop; patients with a known allergy to the manufacturing antibiotics; and patients whose expectations are of a permanent, maintenance-free result. A good surgeon also declines to use it where sutures alone are enough — the comparison explains when that is.

What regulators say

The scaffold is cleared in the United States for soft-tissue reinforcement in plastic and reconstructive surgery and CE-marked in Europe for the same purpose. No mesh or scaffold has a specific clearance for breast augmentation or revision. In November 2023 the FDA wrote to clinicians noting increased use of mesh in breast surgery, stating that it had not determined safety and effectiveness in that setting, asking surgeons to weigh benefit and risk patient by patient, and advising against removing scaffolds from patients with no symptoms. Product-liability litigation about breast mesh exists in the United States; it has produced allegations, not findings, and it is one more reason the consent conversation is explicit rather than reassuring. In Türkiye, as in Europe, use in the breast is within the surgeon's clinical discretion and is documented as such.

Documentation and future care

Every patient who receives a scaffold leaves with its name, size and lot number recorded alongside the implant details, and with the surgeon's note describing where it was placed. Future doctors should know it is there: for imaging it is irrelevant, for a later revision it tells the next surgeon what collagen layer to expect along the fold. Any new swelling, redness, fever or a wound that opens is reported the same day — photographs by WhatsApp are answered the same day. The overview covers what the scaffold is for; this page is the part of the conversation most websites leave out. Questions about your own case go through the assessment.

Frequently Asked Questions

What are the risks of GalaFLEX in breast surgery?

The reported complications are seroma (fluid collection), infection — which, if it does not resolve, may require removing the scaffold — palpable or firm edges in thin tissue, pain or an inflammatory reaction, delayed wound healing and, rarely, exposure through the incision. The longest published series reports an overall complication rate of 8.0 percent and an unplanned reoperation rate of 2.8 percent.

Should GalaFLEX be removed?

Not from patients without symptoms — the FDA said so explicitly in its 2023 letter to clinicians. An infected or exposed scaffold is removed; otherwise it is absorbed by the body within about two years and the question answers itself.

Can I have an MRI or mammogram with GalaFLEX?

Yes. The scaffold is labelled MR-safe and contains no metal. It does not interfere with mammography or ultrasound in the way an implant can, and it is absorbed over time in any case. Tell the radiographer it is there, as with any surgical material.